Impax signs multiproduct agreement with Tolmar

Impax Laboratories president and CEO Larry Hsu said in the past two years, the company has entered into four distinct partnerships for alternative dosage form products.

"Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms," Hsu added.

In 2011, the targeted products had over $1 billion in brand sales, with several of the products having first-to-file or first-to-market potential.

The products and terms of the agreement have not been not disclosed.

Impax Laboratories develops controlled-release and specialty generics in addition to branded products, and Tolmar develops and manufacturers both proprietary and generic pharmaceutical products.